Skip to main content
SpringerLink
Log in

Ceftriaxone: pharmacokinetic advantages allow cost avoidance

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cunha BA. Third-generation cephalosporins: a review. Clin Ther 1992; 14: 616–52

    PubMed  CAS  Google Scholar 

  2. Davis R, Bryson HM. Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections. PharmacoEconomics 1994; 6: 249–69

    Article  PubMed  CAS  Google Scholar 

  3. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. Drug Saf 1993; 9: 132–42

    Article  PubMed  CAS  Google Scholar 

  4. 1994 Physicians GenRx. New York: Data Pharmaceutica Inc: 1994; 401–4

  5. Parker SE, Davey PG. Pharmacoeconomics of intravenous drug administration. PharmacoEconomics 1992; 1: 103–15

    Article  PubMed  CAS  Google Scholar 

  6. Rolston KVI, Jones PG, Fainstein V, et al. Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins. Eur J Clin Microbiol Infect Dis 1991; 10: 139–45

    Article  PubMed  CAS  Google Scholar 

  7. Mangi RJ, Peccerillo KM, Ryan J, et al. Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia. Diagn Microbiol Infect Dis 1992; 15: 441–7

    Article  PubMed  CAS  Google Scholar 

  8. Niebuhr H, Nahrstedt U, Rückert K, et al. Empirical treatment of nosocomial or community-acquired bacterial pneumonia. Chemotherapie 1993; 12: 28–35

    Google Scholar 

  9. Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet 1988; 1: 1305–9

    Article  PubMed  CAS  Google Scholar 

  10. Briceland LL, Outman WR, Nightingale CH, et al. Cost considerations of conversion from aminoglycoside-containing combination regimens to ceftriaxone. DICP Ann Pharmacother 1991; 25; 319–20

    CAS  Google Scholar 

  11. Capri S, Dellamano R. Cost-effectiveness in the hospital use of antibiotics: introductory considerations. J Chemotherapy 1993; 5: 348–51

    CAS  Google Scholar 

  12. Schaison GS. Cost effectiveness of teicoplanin plus ceftriaxone: a once daily antibiotic regimen. Pediatr Infect Dis J 1993; 12: S14–6

    Google Scholar 

  13. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381–96

    Article  PubMed  CAS  Google Scholar 

  14. Wilimas JA, Flynn PM, Harris S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med 1993; 329: 472–6

    Article  PubMed  CAS  Google Scholar 

  15. Poretz DM, Woolard D, Eron LJ, et al. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77: 77–83

    Article  PubMed  CAS  Google Scholar 

  16. Lieu TA, Baskin MN, Schwartz JS, et al. Clinical and cost-effectiveness of outpatient strategies for management of febrile infants. Pediatrics 1992; 89: 1135–44

    PubMed  CAS  Google Scholar 

  17. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26

    Google Scholar 

  18. Mandell LA, Marrie TJ, Niederman MS, et al. Initial antimicrobial treatment of hospital acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4: 317–21

    PubMed  CAS  Google Scholar 

  19. Reeves JH, Russell GM, Cade JF, et al. Comparison of ceftriaxone with cefotaxime in serious chest infections. Chest 1989; 96: 1292–7

    Article  PubMed  CAS  Google Scholar 

  20. Oral ciprofloxacin reduces costs compared with parenteral antibacterials. Drug Ther Perspect 1993 Aug 16; 2(3): 1–4

    Google Scholar 

  21. Jewesson P. Cost-effectiveness and value of an IV switch. PharmacoEconomics 1994; 5 Suppl. 2: 20–6

    Article  PubMed  CAS  Google Scholar 

  22. Ruanguan W, Kunming Y, Qiong S. Antibiotic therapy for typhoid fever. Chemotherapy 1994; 40: 61–4

    Article  PubMed  CAS  Google Scholar 

  23. Zuck P, Rio Y, Ichou F. Efficacy and tolerance of Cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 1990; 26 Suppl. E: 71–7

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ceftriaxone: pharmacokinetic advantages allow cost avoidance. Drugs Ther. Perspect 5, 5–8 (1995). https://doi.org/10.2165/00042310-199505020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505020-00002

Keywords

Search

Navigation